Hepatitis B vaccine Immunogenicity in Kerman 12- month infants

Document Type : Origenal Article

Authors

1 Associate Professor, Department of Pediatrics, Afzalipour school OF Medicine, Kerman University OF Medical Sciences, Kerman, Iran

2 Associate Professor oF Pediatrics, Afzalipour School oF Medicine AND Tropical and Infectious Diseases Research Center, Kerman University oF Medical Sciences, Kerman, Iran

3 MPH, GP, Afzalipour school of Medicine, Kerman University OF Medical Sciences, Kerman, Iran

4 Assistant Professor, Department of Pediatrics, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran

5 Pediatrics Specialist, Sirjan University of Medical Sciences, Kerman, Iran

Abstract

Background:Hepatitis B is the most common chronic viral infection causing mortality in children. Vaccination is the most important prevention strategy. This study was done to determine the antibody level after hepatitis B vaccination in 12-month infants.
Methods: This descriptive study was carried out on 120 healthy 12-month infants in 2014 in Kerman province, Iran. Sex, body weight, birth weight and gestational age were recorded for each infant. Hepatitis B antibody level was measured using ELISA method. Data were analyzed through SPSS16.
Results: Hepatitis B vaccine immunogenicity was 81.7%. In 5% of infants there was no response to the vaccine. Relative immunogenicity was observed in 13.3% of infants. In infants with birth weight greater than 2500 g, the immunogenicity was 86.9%, while in those with birth weight ≤2500 g, it was only 57.1% that shows statistically significant difference. In infants with current weight ≥ 10Kg, the immunogenicity was 60% and in those less than 10Kg, it was 82.6%. This difference was not statistically significant. There was no significant relationship between the immunogenicity based on sex, and gestational age.
Conclusion: In this study, %95 of children had good levels of anti-HBs (≥ 10 IU/L) after vaccination. In addition, immune response was higher in normal birth weight children.

Keywords

Main Subjects

References

1. West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface Antigen. Implication for policy on booster vaccination Vaccine 1996;14(11):1019-1027.
2. Balmasova IP, Yushchuk ND, Mynbaev OA, et al. Immunopathogenesis of chronic hepatitis B. World J Gastroenterol 2014;20(39):14156-14171.
3. Merat S, Rezvan H, Nouraie M, Jamali A, Assari S, Abolghasemi H. The prevalence of hepatitis B surface antigen and anti-hepatitis B core antibody in Iran: a population-based study. Arch Iran Med 2009;12(3):225-31.
4. Schillie SF, Spradling PR, Murphy TV. Immune response of hepatitis B vaccine among persons with diabetes: a systematic review of the literature. Diabetes Care 2012;35(12):2690-7.
5. Lebre F, Borchard G, de Lima MC, Borges O. Progress towards a needle-free hepatitis B vaccine. Pharm Res 2011 May;28(5):986-1012.
6. Ander FE. Summary of safety and efficiency date on a yeast derived hepatitis B vaccine. Am j Med. 1989;87(3): 14S-20S.
7. Alavian SM, Miri SM, Jazayeri SM. Hepatitis B vaccine: prophylactic, therapeutic, and diagnostic dilemma. Minerva Gastroenterol Dietol 2012;58(2):167-78.
8. Taghavinejad F, Rakhshandeh N. Serological markers of hepatitis B in health personnel immunized with recombinant hepatitis B vaccine in Tehran (dissertation). Tehran: Healthy Faculty of Tehran University of Medical Sciences; 2000. [In Persian].
9. Habibzadeh SH, Yazdanband A, Amani F, Rajabi R. Evaluation of response to hepatitis B vaccine in hospital nursing staff, Bu-Ali - Ali Asghar (dissertation). Ardebil: Ardebil University of Medical Sciences; 2004. [In Persian].
10. Broderick AL, Jonas MM. Hepatitis B in children. Semin Liver Dis 2003;23(1):59-68.
11. Centers for Disease Control and Prevention (CDC). Global progress toward universal childhood hepatitis B vaccination, 2003. MMWR Morb Mortal Wkly Rep 2003;52(36):868-70.
12. Harrison GL, Murray-McIntosh R, Penny D. Hepatitis B virus genotypes: a South Pacific perspective. Pac Health Dialog 2001; 8(1):188-92.
13. Moradi A, Khodabakhshi B, Ghaemi E, Mansourian AR, Sarikhani A,Saeidi M. The response rate to hepatitis B vaccine in under one-year children in Gorgan, Iran. Journal of Gorgan University of Medical Sciences 2008; 10 (2):50-53. [In Persian].
14. Azarkar Z. Efficacy of Hepatitis-B vaccine in children from 12 to 16 months in Mashad health centers.Ghazvin University Of Medical Sciences 2004;7(5):38-41.
15. Ahmadi M, Moosavi SM, Jahanfar F. Comparison of antibody level in post hepatitis B vaccination in children with 12-15 and 21-24 months age. Journal of Gorgan University of Medical Sciences 2012; 14(2): 65-69. [in Persian].
16. Cheang HK, Wong HT, Ho SC, Chew KS, Lee WS. Immune response in infants after universal hepatitis B vaccination: a community-based study in Malaysia. Singapore Med  2013;54(4):224-6.
17. Minervini G, McCarson BJ, Reisinger KS, Martin JC, Stek JE, Atkins BM,et al. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy neonates. Vaccine 2012 14;30(8):1476-80.
18. Junqueira AL, Tavares VR, Martins RM et al. Safety and immunogenicity of hepatitis B vaccineadministered into ventrogluteal vs. anterolateral thigh sites in infants: a randomised controlled trial. Int J Nurs Stud 2010;47(9):1074-9.
19. Belloni C, Chirico G, Pistorio A, Orsolini P, Tinelli C, Rondini G. Immunogenicity of hepatitis B vaccine in term and preterm infants. Acta Paediatr 1998 Mar;87(3):336-8.
20. Esmaieli doki M, Zahed pasha Y, Mahdavi A, Haji Ahmadi MComparison of the effect of Hepatitis B vaccination in normal and low birth weight neonates. Babol University Of Medical Sciences 2003;5(2):14-18.
21. Salehi H, Farajzadegan Z. Antibody titer in Iranian children 6 years after hepatitis B vaccine administration. Vaccine 2007; 25(17):3511-4
22. Han K, Shao X, Zheng H, Wu C, Zhu J, Zheng X,et al. Revaccination of non- and low- responders after a standard three dose hepatitis B vaccine schedule. Hum VaccinImmunother 2012;8(12):1845-9.
23. Losonsky GA, Wasserman SS, Stephens I, Mahoney F, Armstrong P, Gumpper K, et al. Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. Pediatrics 1999;103(2):E14.
24. Afsharian M,Ghaderi M,Vaziri S,Leghaei Z,Ghadiri K,Janbaksh A, et al. Immune Response in hepatitis B Vaccine in Children With 6-7 Years.Kermanshah University Of Medical Sciences,2012;15(6):481-488.
25. Hollinger FB. Comprehensive control (or elimination) of hepatitis B virus transmission in the United States.gut 1996;38(Suppl 2):S24-30.
Afzalipour Journal of Clinical Research
Volume 1, Issue 1
October 2017
Pages 62-70

Files

Share

How to cite

Statistics